Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome
- 1Department of Biotechnology, National Institute of Technology Durgapur
Abstract
Polycystic ovary syndrome (PCOS) is a highly prevalent and heterogeneous endocrine disorder affecting women of reproductive age, with substantial reproductive, metabolic, and long-term health consequences. While genome-wide association studies (GWAS) have identified multiple PCOS-associated loci across diverse populations, the functional interpretation of these predominantly non-coding variants and their translation into clinically actionable targets remain unresolved. Here, we present an integrative population-aware framework that systematically combines regulatory functional genomics, long-range chromatin interactions, genome-wide quantitative trait loci, and protein–protein interaction networks to prioritize effector genes underlying PCOS susceptibility. Applying this framework to East Asian and European populations, we demonstrate robust performance relative to existing approaches and uncover both shared and population-specific functions. Notably, our analyses reveal a predominant enrichment of metabolic dysregulation–associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature. These population-specific molecular phenotypes were further supported by transcriptomic data from PCOS patient samples. Importantly, integration of genetic evidence with a network-based approach enabled the identification of druggable targets lacking direct genetic cues. Collectively, our study provides mechanistic insight into the ethnic heterogeneity of PCOS and establishes a scalable strategy for genetically informed, population-specific therapeutic prioritization, advancing precision medicine approaches for women’s health.
Related
- The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis
- Unraveling the therapeutic mechanisms of placenta hominis for polycystic ovary syndrome through network pharmacology, molecular docking, and experimental validation
- Editorial: Chronic large-vessel occlusion in cerebrovascular disease: pathophysiology, diagnosis, and therapeutic advances
- Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia
- Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies.
BibTeX
@article{rajavelu2026gene,
title = {{Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome}},
author = {Sindhuja Rajavelu and Debojyoti De},
journal = {npj Systems Biology and Applications},
year = {2026},
month = jun,
doi = {10.1038/s41540-026-00772-6},
url = {https://doi.org/10.1038/s41540-026-00772-6},
note = {CC BY},
}
RIS
TY - JOUR
TI - Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome
AU - Sindhuja Rajavelu
AU - Debojyoti De
PY - 2026
DA - 2026/06/01
JO - npj Systems Biology and Applications
DO - 10.1038/s41540-026-00772-6
UR - https://doi.org/10.1038/s41540-026-00772-6
AB - Polycystic ovary syndrome (PCOS) is a highly prevalent and heterogeneous endocrine disorder affecting women of reproductive age, with substantial reproductive, metabolic, and long-term health consequences. While genome-wide association studies (GWAS) have identified multiple PCOS-associated loci across diverse populations, the functional interpretation of these predominantly non-coding variants and their translation into clinically actionable targets remain unresolved. Here, we present an integrative population-aware framework that systematically combines regulatory functional genomics, long-range chromatin interactions, genome-wide quantitative trait loci, and protein–protein interaction networks to prioritize effector genes underlying PCOS susceptibility. Applying this framework to East Asian and European populations, we demonstrate robust performance relative to existing approaches and uncover both shared and population-specific functions. Notably, our analyses reveal a predominant enrichment of metabolic dysregulation–associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature. These population-specific molecular phenotypes were further supported by transcriptomic data from PCOS patient samples. Importantly, integration of genetic evidence with a network-based approach enabled the identification of druggable targets lacking direct genetic cues. Collectively, our study provides mechanistic insight into the ethnic heterogeneity of PCOS and establishes a scalable strategy for genetically informed, population-specific therapeutic prioritization, advancing precision medicine approaches for women’s health.
SN - 2056-7189
ER -